PODD$336.84
$337.01
Chart
Performance
Key Stats
AI PODD Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyInsulet Corporation shows strong fundamental performance with consistent revenue growth and improving profitability, supported by positive market trends in diabetes management technology. While valuation metrics are somewhat stretched, its market position and product innovation provide a solid outlook. Technical indicators present a mixed short-term picture, but the long-term trend remains bullish.
Thematic
Insulet benefits from significant secular growth trends in diabetes management, particularly the increasing adoption of continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems. The growing prevalence of diabetes globally and advancements in wearable health technology provide strong tailwinds.
Fundamental
Insulet demonstrates robust revenue growth and a significant improvement in profitability, evidenced by increasing net margins. The company maintains a healthy balance sheet with manageable debt levels and growing cash reserves, providing financial stability and capacity for reinvestment.
Technical
The stock has demonstrated a strong upward trend over the past year. While most short-term moving averages signal a 'Buy', some oscillators are entering 'Sell' or 'Neutral' territory, suggesting potential for a short-term pause or minor pullback before resuming an uptrend.
| Factor | Score |
|---|---|
| Diabetes Management Technology | 95 |
| Wearable Health Devices | 88 |
| Healthcare Innovation | 80 |
| Regulatory Landscape | 75 |
| Factor | Score |
|---|---|
| Revenue Growth | 90 |
| Profitability | 85 |
| Earnings Per Share (EPS) | 80 |
| Balance Sheet Health | 70 |
| Valuation | 50 |
| Cash Flow Generation | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 80 |
| Momentum | 65 |
| Moving Average Convergence Divergence (MACD) | 75 |
| Short-term Oscillators | 40 |
| Support/Resistance Levels | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent Earnings Surprises
Insulet Corporation (PODD) has a history of beating earnings estimates, with 9 out of the last 10 reported quarters showing positive EPS surprises, indicating robust operational execution.
Improving Valuation Metrics
The trailing P/E ratio has decreased from 4384.4 in 2022 to 94.4 TTM, and the forward P/E suggests further normalization, potentially indicating that the stock is becoming more attractively valued relative to its earnings.
Bearish Points (7)
High P/E Ratio
The current P/E ratio (TTM) is 94.4, significantly higher than many industry averages, suggesting that the stock may be overvalued and susceptible to corrections if growth expectations are not met.
Recent Negative Performance
The stock has experienced negative performance over the last month (-7.5%) and 6 months (-3.87%), indicating recent investor sentiment may be shifting or facing headwinds.
Calendar
August 2025
7
Next Earnings Date
H: $1.13
A: $0.93
L: $0.78
H: 619.00M
A: 612.31M
L: 576.20M
Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Seasonals
Price Target
336.01 USD
The 39 analysts offering 1 year price forecasts for PODD have a max estimate of 380.00 and a min estimate of 260.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor in the automated insulin delivery pump market, offering alternative insulin pump systems to Insulet's Omnipod.
Weight: 98
Leading developer of Continuous Glucose Monitoring (CGM) systems, which are increasingly integrated with insulin pumps and crucial for advanced diabetes management.
Weight: 95
Major diversified medical device company with a significant diabetes group offering insulin pumps, CGMs, and diabetes management solutions.
Weight: 92
Develops and manufactures the Freestyle Libre Continuous Glucose Monitoring (CGM) system, a key competitor in the diabetes monitoring space.